9,352 Shares in Gilead Sciences, Inc. $GILD Acquired by Teza Capital Management LLC

Key Points

• Teza Capital Management LLC recently invested approximately $1.05 million in Gilead Sciences by acquiring 9,352 shares during the first quarter.
• Institutional investors now hold 83.67% of Gilead's stock, with Price T Rowe Associates increasing its stake by 314.6% to over $1.6 billion.
• Gilead Sciences announced a quarterly dividend of $0.79 per share, resulting in an annualized yield of 2.7%.

Teza Capital Management LLC acquired a new position in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 9,352 shares of the biopharmaceutical company's stock, valued at approximately $1,048,000.

A number of other institutional investors have also added to or reduced their stakes in GILD. Price T Rowe Associates Inc. MD grew its position in shares of Gilead Sciences by 314.6% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 14,703,103 shares of the biopharmaceutical company's stock valued at $1,647,484,000 after acquiring an additional 11,156,382 shares during the period. Nuveen LLC bought a new position in shares of Gilead Sciences during the 1st quarter valued at approximately $620,415,000. GAMMA Investing LLC grew its position in shares of Gilead Sciences by 13,891.1% during the 1st quarter. GAMMA Investing LLC now owns 2,550,298 shares of the biopharmaceutical company's stock valued at $285,761,000 after acquiring an additional 2,532,070 shares during the period. Los Angeles Capital Management LLC grew its position in shares of Gilead Sciences by 422.6% during the 1st quarter. Los Angeles Capital Management LLC now owns 2,523,036 shares of the biopharmaceutical company's stock valued at $282,706,000 after acquiring an additional 2,040,261 shares during the period. Finally, Royal Bank of Canada grew its position in shares of Gilead Sciences by 30.1% during the 4th quarter. Royal Bank of Canada now owns 8,678,751 shares of the biopharmaceutical company's stock valued at $801,655,000 after acquiring an additional 2,005,863 shares during the period. 83.67% of the stock is owned by institutional investors.

Gilead Sciences Stock Down 1.3%

Shares of GILD traded down $1.51 during trading hours on Friday, hitting $116.36. The company had a trading volume of 1,920,747 shares, compared to its average volume of 8,083,461. The stock has a market capitalization of $144.37 billion, a price-to-earnings ratio of 23.16, a P/E/G ratio of 0.78 and a beta of 0.36. The firm has a fifty day moving average price of $113.97 and a 200-day moving average price of $110.07. Gilead Sciences, Inc. has a 52-week low of $81.57 and a 52-week high of $121.83. The company has a debt-to-equity ratio of 1.13, a quick ratio of 1.15 and a current ratio of 1.32.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last released its quarterly earnings data on Thursday, August 7th. The biopharmaceutical company reported $2.01 earnings per share for the quarter, beating analysts' consensus estimates of $1.96 by $0.05. The business had revenue of $7.08 billion during the quarter, compared to analyst estimates of $6.95 billion. Gilead Sciences had a net margin of 21.86% and a return on equity of 50.99%. Gilead Sciences's revenue was up 1.4% compared to the same quarter last year. During the same period last year, the business earned $2.01 EPS. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. On average, equities research analysts forecast that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, September 29th. Shareholders of record on Monday, September 15th will be issued a $0.79 dividend. The ex-dividend date of this dividend is Monday, September 15th. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.7%. Gilead Sciences's dividend payout ratio (DPR) is presently 62.95%.

Insiders Place Their Bets

In other news, insider Johanna Mercier sold 28,000 shares of the company's stock in a transaction on Friday, August 15th. The stock was sold at an average price of $118.53, for a total transaction of $3,318,840.00. Following the transaction, the insider directly owned 114,168 shares of the company's stock, valued at $13,532,333.04. This represents a 19.70% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CFO Andrew D. Dickinson sold 2,500 shares of the stock in a transaction on Friday, August 15th. The shares were sold at an average price of $118.53, for a total value of $296,325.00. Following the sale, the chief financial officer directly owned 160,110 shares in the company, valued at $18,977,838.30. This trade represents a 1.54% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 82,000 shares of company stock worth $9,371,330 over the last three months. Company insiders own 0.27% of the company's stock.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on GILD. UBS Group increased their target price on shares of Gilead Sciences from $108.00 to $112.00 and gave the company a "neutral" rating in a research report on Friday, August 8th. Daiwa America upgraded shares of Gilead Sciences from a "hold" rating to a "strong-buy" rating in a research note on Tuesday, August 19th. Daiwa Capital Markets raised shares of Gilead Sciences from a "neutral" rating to an "outperform" rating and set a $128.00 target price on the stock in a report on Tuesday, August 19th. Dbs Bank raised Gilead Sciences to a "moderate buy" rating in a report on Friday, September 5th. Finally, Royal Bank Of Canada boosted their price objective on Gilead Sciences from $96.00 to $98.00 and gave the company a "sector perform" rating in a research note on Friday, August 8th. Three investment analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating and six have assigned a Hold rating to the company's stock. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $115.39.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.